Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - Conference on Clarifying Adverse Event Reporting Responsibilities for Medical Devices and Borderline Products (UK) March 2000:

This article was originally published in Clinica

Executive Summary

IIR will hold a conference on Clarifying Adverse Event Reporting Responsibilities for Medical Devices and Borderline Products in London on March 27-28. The meeting will include a keynote address from Joseph Putzeys of the European Commission on implementation of the medical device directives in Europe. There will also be regulatory updates from the UK, France, Germany, Hungary and Norway and practical industry case studies on successfully managing adverse event reporting for medical devices. IIR will also hold a workshop on Overcoming the Practical Challenges of Product Labelling for Medical Devices in London on March 29. For more information contact IIR in UK. Tel: +44 20 7915 5055. Fax: +44 171 915 5001.

You may also be interested in...



RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.

 

 

FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

Topics

UsernamePublicRestriction

Register

MT080181

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel